Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Field Trials

26 Nov 2008 07:00

RNS Number : 9440I
Plant Health Care PLC
26 November 2008
 



26 November 2008

Plant Health Care plc ("Plant Health Care" or the "Company")

Results of the ASA Sponsored N-Hibit Seed Treatment Program

Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries and  the American Soybean Association ("ASA") are pleased to announce that the "N-Hibit® Seed Treatment Satisfaction Guarantee" program during the 2008 growing season was an unqualified success.

The results of the N-Hibit Seed Treatment program over 17 replicated trial sites, ranging from Ohio to Nebraska, produced N-Hibit-treated yields averaging 62.0 bushels/acre compared to the untreated control average of 58.6 bushels/acre. This represents a yield increase of 3.4 bushels/acre or 5.8 per cent. As a consequence, less than 3 per cent. of the acreage treated with N-Hibit resulted in requests for refunds under the Seed Treatment Satisfaction Guarantee Program. The combined effect of nematode reduction and enhanced plant growth are the primary reasons for these excellent results.

ASA President John Hoffman, a soybean producer from WaterlooIowa, commented:

"ASA partnered with PHC on the project because part of ASA's mission is to help identify new ways for ASA members to maximize soybean yield and profitability. N-Hibit's ability to reduce SCN damage and boost overall plant health is consistent with that mission, so ASA worked with PHC to make our members aware of the Satisfaction Guarantee program."

Rick Rice, Plant Health Care Director, Sales & MarketingUSA Agricultural Division stated:

"We wanted growers to share our confidence, and the Satisfaction Guarantee program assured them of a full refund of the purchase price paid for N-Hibit if they weren't fully satisfied with its performance on treated acreage. With a better than 97 percent success rate and the relationships we have developed with all the farmers involved in the program, we couldn't be more pleased." 

The active ingredient in N-Hibit is harpin protein, which stimulates the same plant growth response that occurs when a plant experiences stress. The induced response results in a healthier plant and a reduction in the number of nematodes that host on the roots. Harpin proteins do not enter the plant. They bind with the plant's external harpin protein receptors, which are present on both seed and foliage. After the proteins initiate the plant's natural self defense and growth systems, they harmlessly disintegrate. For more information about PHC, please visit www.planthealthcare.com.

  For more information contact: 

John Hoffman, ASA President +001 (319) 233 9480

John Brady, Plant Health Care plc CEO +001 603 525 3702

Evolution Securities Limited +44 (0)20 7071 4300

Tim Worlledge / Tim Redfern

Tavistock Communications Limited +44 (0)20 7920 3150

Jeremy Carey / Matt Ridsdale

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAAFSAFXPFAE
Date   Source Headline
29th Nov 201312:12 pmRNSDirector's Shareholding
25th Nov 20133:15 pmRNSDivestment of non-core subsidiary
18th Oct 20135:00 pmRNSTR-1 Notification of Major Interest in Shares
30th Sep 20135:00 pmRNSTotal Voting Rights
23rd Sep 201310:30 amRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSAppointment of Adviser
18th Sep 20133:15 pmRNSDirector/PDMR Shareholding
16th Sep 20137:03 amRNSDirectorate Change
16th Sep 20137:00 amRNSHalf Yearly Report
19th Aug 20132:30 pmRNSBlocklisting Interim Review
30th Jul 20137:01 amRNSUpdate on Harpin
30th Jul 20137:00 amRNSPHC announces plans for Harpin seed treatment
22nd Jul 201311:00 amRNSPHC hires Glen Donald as VP Business Development
19th Jul 20137:00 amRNSHead Office Relocation,Research Facility Expansion
15th Jul 20135:15 pmRNSDirector/PDMR Shareholding
5th Jul 20137:00 amRNSUpdate on CISX Listing
3rd Jul 20137:00 amRNSNew Long-Term Incentive Plan and Grant of Awards
7th Jun 20134:15 pmRNSDirectorate Change
31st May 201311:30 amRNSTotal Voting Rights
21st May 201312:00 pmRNSHarpin Granted Federal Registration in Mexico
10th May 20134:45 pmRNSDirector/PDMR Shareholding
9th May 20131:20 pmRNSDirectorate Change
9th May 20131:20 pmRNSResult of AGM
7th May 201310:00 amRNSDirector/PDMR Shareholding
3rd May 20137:00 amRNSDirector/PDMR Shareholding
1st May 20137:00 amRNSDirector/PDMR Shareholding
1st May 20137:00 amRNSTotal Voting Rights
25th Apr 20137:00 amRNSPHC and Arysta LifeScience sign license agreement
19th Apr 20133:30 pmRNSTR-1 Notification of Major Interest in Shares
18th Apr 20133:33 pmRNSTR-1 Notification of Major Interest in Shares
18th Apr 20133:31 pmRNSTR-1 Notification of Major Interest in Shares
18th Apr 20133:31 pmRNSTR-1 Notification of Major Interest in Shares
16th Apr 20138:23 amRNSRe. Investment
15th Apr 20131:30 pmRNSResult of General Meeting
8th Apr 20135:45 pmRNSPublication of Annual Report and Notice of AGM
2nd Apr 20137:00 amRNSConfirmation of Board Changes
27th Mar 20137:00 amRNSPosting of Circular to Shareholders
26th Mar 20134:19 pmRNSBoard Changes
26th Mar 20134:19 pmRNSPlacing and Subscription
26th Mar 20134:18 pmRNSFinal Results
20th Mar 201311:35 amRNSPHC reaches milestone agreement with Germains
11th Mar 20137:00 amRNSMarket Update
19th Feb 20135:45 pmRNSBlock Listing Six-Monthly Return
24th Jan 20139:30 amRNSHarpin field trials results
18th Jan 20135:00 pmRNSNotification of Major Interest in Shares
10th Jan 201312:45 pmRNSTrading Update
31st Dec 201212:25 pmRNSTotal Voting Rights
30th Nov 201211:45 amRNSTotal Voting Rights
2nd Nov 201212:15 pmRNSNotification of Major Interest in Shares
23rd Oct 20127:00 amRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.